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An ATR-dependent G2 checkpoint responds to inhibi-
tion of topoisomerase II and delays entry into mitosis by
sustaining nuclear exclusion of cyclin B1-Cdk1 com-
plexes. Here we report that induction of this checkpoint
with ICRF-193, a topoisomerase II catalytic inhibitor
that does not cause DNA damage, was associated with
an ATR-dependent inhibition of polo-like kinase 1 (Plk1)
kinase activity and a decrease in cyclin B1 phos-
phorylation. Expression of constitutively active Plk1
but not wild type Plk1 reversed ICRF-193-induced mi-
totic delay in HeLa cells, suggesting that Plk1 kinase
activity is important for the checkpoint response to
ICRF-193. G2/M synchronized normal human fibroblasts,
when treated with ICRF-193, showed a decrease in cy-
clin B1 phosphorylation and Plk1 kinase activity despite
high cyclin B1-Cdk1 kinase activity. G2 fibroblasts that
were treated with caffeine to override the checkpoint
response to ICRF-193 displayed a high incidence of
chromosomal aberrations. Taken together, these results
suggest that ATR-dependent inhibition of Plk1 kinase
activity may be one mechanism to regulate cyclin B1
phosphorylation and sustain nuclear exclusion during
the G2 checkpoint response to topoisomerase II inhibi-
tion. Moreover, the results demonstrate an important
role for the topoisomerase II-dependent G2 checkpoint
in the preservation of human genomic stability.
Cell cycle checkpoints are surveillance systems that ensure
orderly and timely replication and segregation of the genome.
G2 checkpoint systems prevent inappropriate mitotic entry
when there are abnormalities in DNA due to incomplete DNA
replication, insufficient chromatid decatenation, or DNA dam-
age (1–4). The phosphatidylinositol 3-kinase family of protein
kinases includes ATM (ataxia telangiectasia-mutated) and
ATR (A-T and rad3-related), which are proximal to DNA ab-
normalities and send signals to regulate the mitosis-promoting
cyclin B1-Cdk1 complex during G2 checkpoint responses.
After DNA damage, one mechanism of G2 checkpoint control
involves regulation of cyclin B1-Cdk1 kinase activity. At the
onset of mitosis, cyclin B1-Cdk1 kinase becomes active when
the dual specificity phosphatase, Cdc25C, removes inhibitory
phosphorylations on Cdk1. Once active, cyclin B1-Cdk1 com-
plexes phosphorylate Cdc25C, which enhances its phosphatase
activity. This results in an autocatalytic feedback loop and,
therefore, generates a burst of cyclin B1-Cdk1 kinase activity
that drives progression into mitosis. The G2 checkpoint carries
out cell cycle arrest in part by inhibiting the activity of cyclin
B1-Cdk1 complexes through the effector kinase Chk1. After
DNA damage and replication blocks, Chk1 is phosphorylated
and activated by ATR and possibly ATM (5–8). Chk1 phospho-
rylates Cdc25C in a 14-3-3 binding site, which causes 14-3-3 to
sequester Cdc25C away from cyclin B1-Cdk1 and prevents
activation of cyclin B1-Cdk1 complexes (9, 10). Initiation of the
cyclin B1-Cdk1 autoamplification loop requires prior activation
of Cdc25C. The kinase that first activates Cdc25C (the mitotic
trigger kinase) has not been rigorously identified, although
some evidence points to polo-like kinase 1 (Plk1).1
Polo-like kinases are a conserved group of protein kinases
that are involved at several points in mitotic progression. They
are thought to function in diverse processes such as the G2 to M
cycle transition, centrosome assembly and separation, forma-
tion of the mitotic spindle, activation of the anaphase-promot-
ing complex, and cytokinesis (11, 12). Human and Xenopus
polo-like kinases (Plk1 and Plx1, respectively) have been pro-
posed to initiate mitosis by activating Cdc25C and participat-
ing in the Cdc25C/cyclin B1-Cdk1 amplification loop (13–16).
The regulation of cyclin B1-Cdk1 kinase activity during the G2
checkpoint has been suggested to occur through inhibition of
Plk1 activity, which would presumably result in an inability of
Cdc25C phosphatase to activate cyclin B1-Cdk1 complexes.
Evidence supporting a role for regulation of Plk1 in the G2
checkpoint includes the findings that cells experiencing a DNA
damage-induced mitotic delay displayed an associated decrease
in Plk1 kinase activity, and overexpression of a constitutively
active mutant of Plk1 reversed the mitotic delay (17). More-
over, Plk1 activity was decreased in an ATM- and/or ATR-de-
pendent manner after treatment of cells with radiomimetic
drugs and UVC, respectively (18).
Another mechanism of G2 checkpoint control independent of
cyclin B1-Cdk1 activity is nuclear exclusion of cyclin B1. At the
onset of mitosis, phosphorylation of cyclin B1 causes an inhi-
bition of nuclear export and enhanced nuclear import, resulting
in a net accumulation of cyclin B1-Cdk1 complexes in the
nucleus (19–23). Interfering with nuclear exclusion of cyclin B1
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and down-regulation of Cdk1 kinase activity were required to
significantly reverse the DNA damage G2 checkpoint in HeLa
cells (23, 24). In the Xenopus system, phosphorylation of Ser-
113 (analogous to Ser-147 in human cyclin B1), which resides
within the cyclin B1 nuclear export sequence, interfered with
the ability of the Crm1 nuclear receptor to bind to cyclin B1 and
thereby inhibited nuclear export (25). Plk1 was recently shown
to phosphorylate human cyclin B1 at Ser-147 and promote its
nuclear accumulation (26). Thus, activation of Plk1 in G2 ap-
pears to drive mitotic progression by promoting the accumula-
tion of cyclin B1 in the nucleus in addition to participating in
the Cdc25C-cyclin B1-Cdk1 autocatalytic feedback loop. The G2
checkpoint may regulate the sub-cellular compartmentaliza-
tion of cyclin B1-Cdk1 by controlling the phosphorylation sta-
tus of cyclin B1 through inhibition of Plk1 activity.
The bisdioxopiperazine, ICRF-193, is a topoisomerase II in-
hibitor that does not cause DNA damage but rather appears to
block topoisomerase II at a point in its catalytic cycle after
strand passage and religation but before release of the passed
DNA and ATP hydrolysis (27). Therefore, ICRF-193 sequesters
topoisomerase II in a “closed-clamp” conformation that tethers
two DNA strands and blocks additional cycles of strand pas-
sage (27). A checkpoint is activated in G2 when topoisomerase
II is inhibited with ICRF-193 (3, 4). The topoisomerase II-de-
pendent G2 checkpoint response to ICRF-193 was recently re-
ported to be distinct from the DNA damage G2 checkpoint as it
was ATM-independent and did not appear to be enforced
through inhibition of cyclin B1-Cdk1 kinase activity. Rather, it
was suggested that ATR-dependent signaling acted to sustain
the nuclear exclusion of cyclin B1-Cdk1 complexes (4). In this
report, we show that inhibition of Plk1 kinase activity occurs in
an ATR-dependent manner in cells arrested in G2 by ICRF-193.
The mitotic delay response to ICRF-193 was reversed in cells
expressing constitutively active Plk1 alleles, strongly suggest-
ing that Plk1 kinase is an important element of the topoisomer-
ase II-dependent G2 checkpoint. G2 cells arrested with ICRF-
193 also displayed reduced serine phosphorylation of cyclin B1
in vivo and reduced kinase activity on cyclin B1 in cell-free
extracts. Taken together these data support a model for the
topoisomerase II-dependent G2 checkpoint whereby ATR sig-
naling inhibits Plk1 activity, which in turn blocks the phospho-
rylation of cyclin B1 and prevents the accumulation of nuclear
cyclin B1-Cdk1 complexes.
EXPERIMENTAL PROCEDURES
Cell Culture, Synchrony, Metaphase Preparation, and Transfec-
tions—NHF1-hTERT cells were maintained in minimum Eagle’s me-
dium supplemented with 10% fetal bovine serum (FBS) and 2 mM
glutamine. For synchrony experiments, NHF1-hTERT cells were grown
to confluence arrest and then released into 2 g/ml aphidicolin for 24 h
after which they were rinsed 3 times with phosphate-buffered saline
(PBS) (28). Fresh culture media was then added and the cells were
returned to the incubator for 8 h. Cells were determined to be in the G2
phase of the cycle as evidenced by 4N DNA content with very few cells
staining for the mitotic marker, phospho-histone H3. G2 phase cells
were harvested or incubated with 0.01% Me2SO or 2 M ICRF-193 in
the presence of 100 ng/ml Colcemid for an additional 4 h. Cells were
prepared for metaphase spreads as previously described (29). The AT
diploid fibroblast cell line (GM03395) was maintained in minimum
Eagle’s medium supplemented with 20% FBS and 2 mM L-glutamine.
GM847 cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS, 2 mM glutamine, and 0.4 mg/ml G418
sulfate (30). For induction of kinase-inactive ATR allele, ATRki, 5.0 
105 cells were plated into 100-mm dishes, and 1 g/ml doxycycline was
added for 48 h. HeLa cells were maintained in minimum Eagle’s me-
dium containing 10% FBS and 2 mM L-glutamine. For transfections,
cells were plated at a density of 8.0  105 cells/60-mm dish. After
plating, cells were transfected with 0.5 g of GFP-H2B plasmid to-
gether with 2 g of control vector (pBABE plasmid DNA) or 2 g of one
of the Myc-tagged Plk-1 plasmids (wild type, T210D, or T210D and
S137D (TDSD)) (17) using Polyfect (Qiagen) according to the manufac-
turer’s recommendations. Forty-eight hours after transfection, cells
were either harvested for Western blot analysis, or ICRF-193-induced
G2 arrest was assessed. Cells were incubated with Me2SO or 2 M
ICRF-193 for 2 h, and then mitotic index was quantified.
Immunoprecipitation and Western Immunoblot Analysis—For deter-
mination of serine phosphorylation of endogenous cyclin B1, this pro-
tein was immunoprecipitated from 200 g of total cell extract using a
cyclin B1 monoclonal antibody (Upstate Biotechnology). Immunopre-
cipitates were then subjected to SDS-PAGE analysis (8% polyacryl-
amide gel) and immunoblotted with rabbit polyclonal anti-serine anti-
body (1:1000, Zymed Laboratories Inc.).
Mitotic Index Determination—Mitotic cells were quantified via flow
cytometric analysis of cells with 4N DNA that stained positive for the
mitotic epitope phospho-histone H3 (31). Briefly, cells were harvested,
rinsed with PBS, then resuspended in 1% formaldehyde in PBS and
incubated for 20 min at room temperature. Fixed cells were then rinsed
once with PBS and stored in 70% ethanol at 4 °C. At the time of
staining, cells were rinsed in PBS, pelleted, and resuspended in PBS
containing 0.5 g of anti-phospho-histone H3 antibody (Upstate Bio-
technology), 5% FBS, 0.1% sodium azide, and NaCl (IFA solution) and
incubated for 2 h at room temperature. Cells were then rinsed twice in
IFA, resuspended in fluorescein isothiocyanate-labeled anti-mouse an-
tibody diluted 1:20 (Santa Cruz) in IFA, and incubated for 1 h at room
temperature in the dark. After 2 washes in IFA, cells were resuspended
in IFA containing propidium iodine (PI) (0.5 g/ml) and RNase (2.5
g/ml) and incubated at 37 °C for at least 30 min. For experiments with
transfected HeLa cells, cells were fixed with 90% ethanol and 2.5%
acetic acid in PBS for 20 min at room temperature. Cells were then
rinsed with PBS, and nuclei were stained with DAPI (4,5-diamidino-
2-phenylindole dihydrochloride). The fraction of mitotic cells in 2000
GFP-positive cells was determined by fluorescence microscopy.
Cyclin B1-Cdk1 Kinase Assay—Cyclin B1-associated Cdk1 kinase
activity assays were performed as previously described (4, 32).
Polo-like Kinase Activity Assay—Cells were lysed in buffer contain-
ing 50 mM Tris, pH 7.4, 1% Nonidet P-40, 250 mM NaCl, 10 mM NaF,
and 5 mM EDTA and incubated on ice for 20 min. Cell lysates were
clarified by centrifugation at 45,000 rpm for 20 min. Plk1 was immu-
noprecipitated using 1 g of a rabbit anti-Plk1 antibody (a generous gift
from Doug Ferris, National Cancer Institute, National Institutes of
Health or from Upstate Biotechnology) from 300–500 g of total pro-
tein. Samples were precleared for 30 min with protein G beads previ-
ously washed in 10 PBS and 1 kinase buffer. Samples were incu-
bated with anti-Plk1 antibody for 2 h at 4 °C, after which 20 l of
protein G beads was added. After 30 min, samples were washed four
times with kinase buffer and once in reaction buffer (20 mM Hepes, pH
7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM EGTA, 0.5 mM dithiothreitol, 5
mM NaF, 10 nM orthovanadate). Samples were then incubated with 20
l of kinase buffer, 5 mg of dephosphorylated -casein (Sigma), and 1
Ci of [-32P]ATP at 34 °C for 50 min. The kinase reaction was stopped
by the addition of 2 Laemmli sample buffer, and samples were sub-
jected to SDS-PAGE (12% acrylamide gel) and autoradiography.
In Vitro Cyclin B1 Kinase Assay—Cells were lysed in kinase lysis
buffer containing 20 mM Tris, pH 7.5, 10 mM EGTA, 10 mM MgCl2, 0.1%
Nonidet P-40, 1 mM dithiothreitol, 1 mM NaVO4, 10 mM -glycerophos-
phate, 20 g/ml aprotinin, 1 M okadaic acid, 10 mg/ml leupeptin, 1 M
AEBSF (4-(2-aminoethyl)benzenesulfonyl fluoride; Sigma) and centri-
fuged at 14,000 rpm for 20 min. Cell extract (200 g) was then incu-
bated with 100 M cold ATP, 15 mM MgCl2, and 2 Ci of [-
33P]ATP for
45 min at 30 °C. Cyclin B1 was immunoprecipitated from the kinase
reaction by adding 1 g of cyclin B1 monoclonal antibody (Upstate
Biotechnology) and lysis buffer and incubating for 2 h at 4 °C. Protein
G beads (Sigma) were added, and samples were incubated for an addi-
tional 30 min, after which the beads were washed 4 times with kinase
lysis buffer. Cyclin B1 immunoprecipitates were then subjected to SDS-
PAGE (8% acrylamide gel) and autoradiography.
RESULTS
ICRF-193 Prevents Mitotic Entry and Plk1 Activation in Syn-
chronized Human Fibroblasts—Plk1 activity levels are low in
G1 and S phase but start to rise in G2 and peak in mitosis (33,
34). Because Plk1 activity is regulated by the DNA damage
checkpoint and one function of Plk1 involves regulation of
cyclin B1 localization, we determined whether ICRF-193-in-
duced mitotic delay was associated with an inhibition of Plk1
activity. Normal human fibroblasts expressing telomerase
(NHF1-hTERT) were synchronized to the G2 phase of the cell
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cycle and then incubated with ICRF-193 or solvent in the
presence of Colcemid for an additional 4 h. Under these condi-
tions there were few cells in the G2 phase population that
stained positive for the mitotic marker, phospho-histone H3
(0.1%) (Fig. 1A). Me2SO-treated control cells accumulated in
mitosis 8–12 h after release from aphidicolin (53%) (Fig. 1A).
Treatment of G2 phase cells with ICRF-193 produced a severe
inhibition of entry into mitosis compared with the control cells
(89%, p  0.001), as reflected by the low mitotic index (4.5%)
(Fig. 1, A and C). As expected, Plk1 activity was low in G2-
phase cells and significantly increased in control cells that had
progressed to mitosis (Fig. 1B). Cells treated with ICRF-193
displayed a significant inhibition of Plk1 activity compared
with the control Me2SO-treated mitotic cells (34% of control,
p  0.006) (Fig. 1C). It is important to note that ICRF-193-
treated cells displayed higher Plk1 activity than cells har-
vested 4 h earlier at the beginning of G2 (Fig. 1B), indicating
that Plk1 activation was not completely prevented by the
ICRF-193-induced checkpoint.
ICRF-193-induced Inhibition of Plk1 Activity Is Not Associ-
ated with a Significant Inhibition in Cyclin B1-Cdk1 Activi-
ty—It has been suggested that inhibition of Plk1 activity dur-
ing G2 checkpoint responses may control mitotic entry through
regulation of cyclin B1-Cdk1 activity (17, 18). Given that we
have previously reported a mitotic delay response to topoi-
somerase II inhibition with ICRF-193 despite high cyclin B1-
Cdk1 kinase activity in log phase NHF1-hTERT fibroblasts and
other human cell types (4), we investigated whether ICRF-193-
induced inhibition of Plk1 activity was associated with an
inhibition of cyclin B1 activity in synchronized cells. In syn-
chronized NHF1-hTERT fibroblasts, cyclin B1-Cdk1 activity
was low in G2 phase cells and high in mitotic cells (Fig. 1B).
Cells undergoing an ICRF-193-induced mitotic delay displayed
a substantial increase in cyclin B1-Cdk1 kinase activity when
compared with G2-phase cells harvested 4 h earlier (Fig. 1B).
Consistent with our previous report in log-phase cells (4), G2-
phase fibroblasts arrested with ICRF-193 displayed only a
small inhibition of cyclin B1-Cdk1 kinase activity (28%, p 
0.14) compared with the control cells allowed to accumulate in
mitosis (Fig. 1B). These findings taken together with the ob-
servation of strong inhibition of Plk1 kinase activity (66%) (Fig.
1C) suggest that inhibition of Plk1 activity and cyclin B1-Cdk1
activation during the topoisomerase II-dependent G2 check-
point response are not directly linked.
Plk1 Activity during the ICRF-193-induced Checkpoint Re-
sponse Is ATR-dependent—It was recently reported that inhi-
bition of Plk1 activity after treatment of cells with DNA-dam-
aging agents occurs in an ATM- and ATR-dependent manner
(18). Because ATR was recently shown to be the relevant ki-
nase that enforced the topoisomerase II-dependent G2 check-
point (4), we next investigated whether ICRF-193-induced in-
hibition of Plk1 activity was mediated by ATR. AT cells have
been previously shown to display a normal G2 checkpoint re-
sponse to ICRF-193 (4). Therefore, as expected, the inhibition
of Plk1 activity observed after treatment with ICRF-193 was
independent of ATM signaling (Fig. 2, top panel). AT cells
(GM03395) treated with ICRF-193 displayed an ICRF-193-
induced inhibition of Plk1 kinase activity (57% of Me2SO con-
trol) (Fig. 2, top panel). The ICRF-193-induced inhibition of
Plk1 activity observed in NHF1-hTERT cells was reversed in
the presence of 2 mM caffeine, an inhibitor of ATM and ATR
(data not shown). Taken together, these observations implied
that regulation of Plk1 activity during the topoisomerase II-de-
pendent checkpoint was ATR-dependent. To determine directly
FIG. 1. ICRF-193 inhibits entry into mitosis, and Plk1 activity
in synchronized normal human fibroblasts. NHF1-hTERT cells
were synchronized to the G2 phase of the cell cycle then harvested
directly or further incubated with Me2SO or 2 M ICRF-193 in the
presence of 100 ng/ml of Colcemid for 4 h. M and I denote control
Me2SO-treated mitotic and ICRF-193-treated, respectively. A, mitotic
index was determined via flow cytometric analysis using propidium
iodine to stain DNA (x axis) and an antibody against phosphorylated
histone H3 to stain mitotic cells (y axis) as described under “Experi-
mental Procedures.” The histogram shows the result from five experi-
ments (mean  S.D.). FITC, fluorescein isothiocyanate. B, Plk-1-asso-
ciated casein kinase activity and cyclin B1-Cdk1-associated histone H1
kinase activity (HH1) were assessed as described under “Experimental
Procedures.” The autoradiographs are representative of three inde-
pendent experiments for Plk1 and five independent experiments for
cyclin B1-Cdk1. C, mitotic, index, Plk1 activity, and cyclin B1-Cdk1
kinase activity observed in ICRF-treated cultures were expressed as
percentages of the correspondent values observed in cultures exposed
only to the Me2SO solvent. *, the results observed in the ICRF-193-
treated samples compared with the Me2SO controls were significantly
different for mitotic index (analysis of matched pairs, p  0.001) and
Plk1 activity (analysis of matched pairs, p  0.006) but not for cyclin
B1-Cdk1 activity (analysis of matched pairs, p  0.143).
FIG. 2. ATR regulates Plk1 activity during the topoisomerase
II-dependent G2 checkpoint response. Top panel, AT fibroblasts
(GM03395) were incubated with Me2SO or 2 M ICRF-193 for 2 h, after
which Plk1 kinase activity was determined as described under “Exper-
imental Procedures.” The results show the mitotic index in ICRF-193-
treated cells expressed as a percentage of the Me2SO-treated control.
Bottom panel, non-induced (dox) and induced (dox) GM847 cells
were incubated with Me2SO or 2 M ICRF-193 for 2 h, after which Plk1
kinase activity was assessed as described under “Experimental Proce-
dures.” The autoradiograph shown is representative of all experiments.
The values of Plk1 activity determined in ICRF-193-treated cells in 4
independent experiments were expressed as the percentage of the Plk1
activity in Me2SO-treated cells. Averages ( S.E.) are shown for non-
induced and induced GM847 cells.
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whether ATR mediates the ICRF-193-induced inhibition of
Plk1 activity, Plk1 kinase assays were performed in GM847
fibroblasts containing an inducible kinase-inactive ATR allele
(ATRki). Treatment of non-induced GM847 fibroblasts with
ICRF-193 caused a significant inhibition in Plk-1 kinase (63%
of control) (Fig. 2, bottom panel). However, cells induced to
overexpress ATRki failed to display the ICRF-193-induced in-
hibition of Plk1 activity (Fig. 2, bottom panel). Like mitotic
entry, Plk1 activity was inhibited in an ATR-dependent man-
ner by the topoisomerase II-dependent checkpoint response.
Overexpression of Constitutively Active Plk1 Reverses ICRF-
193-induced Checkpoint Function—Plk1 is activated by phos-
phorylation on serine and threonine residues that lie within a
conserved activation loop (17). Mutation of Thr-210 (T210D) or
both Thr-210 and Ser-137 to aspartic acid (TDSD) to mimic
phosphorylation has been reported to result in constitutive
activation of Plk1 (17). Overexpression of these alleles in U20S
cells reversed the DNA damage-induced mitotic delay, which
implied that Plk1 is a target of the DNA damage checkpoint
(17). To demonstrate directly that regulation of Plk1 activity
was required for ICRF-193-induced checkpoint function, we
tested the ability of human cells overexpressing wild type or
constitutively active Plk1 alleles to undergo an ICRF-193-in-
duced mitotic delay. To circumvent the problem of G1 arrest
due to the transfection protocol in NHF1-hTERT fibroblasts,
HeLa cells lacking functional p53 were used for these experi-
ments. These HeLa cells had previously been shown to respond
to ICRF-193 with a mitotic delay similar to that seen in NHF1-
hTERT cells (4). HeLa cells were co-transfected with either
Myc-tagged wild type Plk1, Myc-tagged constitutively active
Plk1 (T210D or TDSD), or an empty vector plasmid (pBABE)
together with a GFP-histone H2B fusion protein (Fig. 3A). The
transfection efficiency was equivalent between alleles and var-
ied from 12 to 20% between experiments. This is illustrated by
the low signal of Myc-tagged Plk1 compared with the endoge-
nous Plk1 observed on the immunoblot from total HeLa cell
extracts (Fig. 3A). To account for the low transfection effi-
ciency, only cells positive for GFP-H2B expression were exam-
ined for ICRF-193-induced mitotic delay. Treatment with
ICRF-193 resulted in a 49% inhibition of mitosis in GFP-H2B-
positive cells and a 40% inhibition of mitosis in GFP-H2B-
positive cells expressing the wild type Plk-1 (Fig. 3B). GFP-
H2B cells expressing the constitutively active Plk1 mutants
(T210D or TDSD) displayed no inhibition of mitosis after treat-
ment with ICRF-193 (98% of control and 105% of control,
respectively) (Fig. 3B). Thus, inhibition of Plk1 activity is re-
quired for the topoisomerase II-dependent checkpoint.
Plk1-dependent Cyclin B1 Phosphorylation Is Inhibited dur-
ing the Checkpoint Response to ICRF-193—One function of
Plk1 is to phosphorylate cyclin B1 and promote its nuclear
accumulation (26). Thus, we hypothesized that regulation of
Plk1 activity during the checkpoint response to ICRF-193 con-
trols the localization of cyclin B1-Cdk1 complexes by regulating
the phosphorylation status of cyclin B1. To test whether treat-
ment with ICRF-193 inhibits serine phosphorylation of cyclin
B1 in vivo, cyclin B1 was immunoprecipitated from synchro-
nized fibroblasts, then SDS-PAGE and immunoblots were per-
formed using a phosphoserine antibody. As expected, serine
phosphorylation on cyclin B1 was not observed in G2-phase
cells but was present in mitotic control cells (Fig. 4A). The
serine phosphorylation on cyclin B1 was severely diminished in
cells that experienced an ICRF-193-induced mitotic delay (Fig.
4A). The phosphorylation of cyclin B1 has been shown to be due
to the activity of kinases active in mitosis (20). To investigate
whether the ICRF-193-induced checkpoint inhibits kinases
that phosphorylate cyclin B1 in vitro, kinase activity toward
endogenous cyclin B1 was assessed in cell-free extracts from
NHF1-hTERT fibroblasts that were synchronized with the reg-
imen described above. Kinase activity toward endogenous cy-
clin B1 in extracts of synchronized mitotic cells was quite high
(15 elevated) compared with that detected in extracts from
G2-phase cells that had been harvested 4 h earlier (Fig. 4B).
Cyclin B1 phosphorylation was slightly increased in extracts
from ICRF-193-treated cells when compared with G2-phase
cells (3.3 elevated). However, in extracts from cells that had
FIG. 3. Inhibition of Plk1 activity is required for the topoi-
somerase II-dependent G2 checkpoint response. HeLa cells were
transfected with GFP-H2B together with pBABE, wtPlk1, T210D, or
TDSD plasmids, as described under “Experimental Procedures.” 48 h
after transfection, cells were incubated with Me2SO or 2 M ICRF-193
for 2 h, then harvested for Western immunoblot analysis (A) or fixed for
mitotic index determination, which was quantified by examining GFP-
stained nuclei using a fluorescent microscope. The results in B show the
mitotic index in ICRF-193-treated cells expressed as a percentage of the
mitotic index in the Me2SO-treated cells (mean  S.D., n  3).
FIG. 4. The topoisomerase II-dependent G2 checkpoint inhibits
cyclin B1 phosphorylation in vivo and in vitro. Synchronized G2
phase NHF1-hTERT fibroblasts were harvested directly or further in-
cubated with Me2SO or 2 M ICRF-193 in the presence of 100 ng/ml of
Colcemid for 4 h. At the time of harvest, cells were stored as dry pellets
at 80 °C until kinase assays or immunoprecipitation immunoblots
were performed. I and M denote ICRF-193-treated and Me2SO-treated
mitotic phase cells respectively. A, cyclin B1 was immunoprecipitated
from cell lysates as described under “Experimental Procedures,” and
immunoblot analysis was performed using antibodies to phosphoserine
and cyclin B1. B, in vitro cyclin B1 phosphorylation was determined as
described under “Experimental Procedures.” The autoradiograph is rep-
resentative of four independent experiments. Results show the mean
( S.E., n  4) increment in kinase activity relative to the G2 phase
cells.
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been treated with ICRC-193, the ability of a kinase or kinases
to phosphorylate endogenous cyclin B1 was significantly inhib-
ited (27% of mitotic control) (Fig. 4B). Immunodepletion of Plk1
from mitotic cell extracts has been previously shown to abolish
phosphorylation of cyclin B1 on Ser-133 and Ser-147 (26). Im-
munodepletion of Plk1 in extracts from Me2SO-treated mitotic
NHF1-hTERT cells did not completely inhibit the phosphoryl-
ation of cyclin B1 in this system (data not shown). This result
was not surprising because other kinases such as cyclin B1-
Cdk1 are able to phosphorylate the first two serines within the
cyclin B1 cytoplasmic retention sequence. In combination,
these findings suggest that the topoisomerase II-dependent
checkpoint prevents a kinase or kinases from phosphorylating
serines on cyclin B1.
Bypass of the ICRF-193-induced Checkpoint with Caffeine
Promotes Clastogenesis—ATR is essential for stabilization of
the genome during the cell cycle, because disruption of ATR
function results in the destabilization of chromosomes and cell
death (4, 35). One function of ATR is to enforce the ICRF-193-
induced checkpoint (4). Because the consequences of defective
topoisomerase II-dependent checkpoint function have not been
investigated in normal human cells, the effect of blocking ATR-
dependent G2 checkpoint function in NHF1-hTERT fibroblasts
was investigated. NHF1-hTERT cells were synchronized to G2
as described above. ICRF-193 or Me2SO were added to the
cultures in the presence of 2 mM caffeine, a concentration
known to inhibit ATR kinase activity and reverse ICRF-193-
induced checkpoint function in normal human fibroblasts (36).2
The cells were incubated for an additional 4 h in the presence
of Colcemid to capture the mitotic cells. No chromosomal aber-
rations were observed in 25 metaphases from mitotic control
cells incubated with caffeine (Fig. 5). However, metaphases
from ICRF-193-treated cells that were incubated with caffeine
to bypass the checkpoint were abnormal. The chromosomes
from ICRF-193-treated cells were much longer and less con-
densed than those from Me2SO-treated mitotic cells (Fig. 5).
Moreover, 20% of the metaphases from the ICRF-193-treated
cells contained chromosomes that were all unifilar, that is, the
sister chromatid cores had not separated. These results are
consistent with a requirement for topoisomerase II in chroma-
tid condensation (37, 38). The remaining 80% of metaphases
contained only bifilar chromosomes. Bifilar chromosomes from
cells incubated with ICRF-193 in the presence of caffeine dis-
played aberrant structural features and frank damage (Fig. 5).
All of the metaphases with bifilar chromatids exhibited con-
strictions or tangles between sister chromatids (Fig. 5). Fifty-
six percent of the metaphases contained chromatid breaks and
60% contained exchanges. As shown in Fig. 5, some of the
breaks appeared to occur at the site of a constriction.
DISCUSSION
The findings presented here demonstrate that Plk1 kinase
activity and cyclin B1 phosphorylation are regulated by a to-
poisomerase II-dependent G2 checkpoint. Progression of syn-
chronized human fibroblasts from G2 to M was associated with
activation of Plk1, and this activation was inhibited when cells
were treated with ICRF-193 to inhibit topoisomerase II cata-
lytic activity. The regulation of Plk1 activity observed in cells
experiencing an ICRF-193-induced G2 arrest was ATR-depend-
ent because expression of a kinase-inactive ATR allele reversed
the ICRF-193-induced inhibition of Plk1 kinase activity. Ex-
pression of constitutively active Plk1 mutants reversed the
ICRF-193-induced mitotic delay, demonstrating that the inhi-
bition of Plk1 kinase activity observed after treatment with
ICRF-193 was not merely due to an inability of the cells to
enter mitosis. This finding provides genetic evidence that inhi-
bition of Plk1 activity is required for the topoisomerase II-de-
pendent G2 checkpoint. Inhibition of mitosis and Plk1 activity
in the presence of high cyclin B1-Cdk1 activity occurred in
synchronized human fibroblasts that were treated with ICRF-
193. Moreover, treatment of G2 cells with ICRF-193 also re-
sulted in an inhibition of cyclin B1 phosphorylation. These
observations support a model for the topoisomerase II-depend-
ent G2 checkpoint whereby ATR signals to inhibit Plk1 activity,
which in turn prevents the phosphorylation of cyclin B1 and,
thus, sustains nuclear exclusion of cyclin B1-Cdk1 complexes
(Fig. 6).
Nuclear exclusion of cyclin B1-Cdk1 complexes was previ-
ously reported to be an important component of topoisomerase
II-dependent G2 checkpoint function (4). Phosphorylation at
four serines within cyclin B1 is required for nuclear accumu-
lation of cyclin B1-Cdk1 complexes at the beginning of mitosis
(19–22, 25). In support of the hypothesis that one mechanism
for checkpoint-enforced nuclear exclusion of cyclin B1-Cdk1
complexes is to prevent the phosphorylation of cyclin B1, serine
phosphorylation of cyclin B1 was impaired in checkpoint-ar-
rested cells. Plk1 has recently been shown to phosphorylate
cyclin B1 on Ser-147 and target it to the nucleus during
prophase in human cells (26). It was suggested that this phos-2 P. B. Deming and W. K. Kaufmann, unpublished observations.
FIG. 5. Bypass of the topoisomerase II-dependent G2 check-
point with caffeine promotes clastogenesis. Synchronized G2
phase NHF1-hTERT cells were incubated with Me2SO (DMSO) or 2 M
ICRF-193 in the presence of 2 mM caffeine and 100 ng/ml Colcemid for
4 h. Cells were then harvested, and metaphase spreads were prepared
as described under “Experimental Procedures.” The arrows point to
constrictions, and arrowheads point to breaks and exchanges. The dou-
ble arrow is an example of a break at a constriction site. Num., the
numbers of events in 25 cells; %, the percent of cells with such an event.
FIG. 6. Model of topoisomerase II-dependent G2 checkpoint
function. P, phosphorylation.
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phorylation event resulted in inactivation of the nuclear export
sequence (26). This is consistent with the finding in the Xeno-
pus system that phosphorylation of Ser-113 resulted in the
inability of cyclin B1 to bind to the Crm1a nuclear export
receptor (25). Plk1 activity was inhibited in ICRF-193-treated
cells, and the phosphorylation of cyclin B1 in mitotic cell ex-
tracts was diminished when Plk1 was immunodepleted from
the reaction, suggesting that the ICRF-193-induced checkpoint
regulates cyclin B1 localization at least in part through inhibi-
tion of Plk1 activity. Cyclin B1-Cdk1 itself has been reported
to phosphorylate in vitro the first two serines within the cyto-
plasmic retention sequence of cyclin B1 (19, 21, 25, 39, 40).
Cells arrested in G2 with ICRF-193 are able to sustain nuclear
exclusion of cyclin B1-Cdk1 complexes (4) and significantly
inhibit cyclin B1 phosphorylation despite high cyclin B1-Cdk1
activity. Therefore, it does not seem likely that autophospho-
rylation of cyclin B1 is the rate-limiting event in vivo that
promotes cyclin B1 nuclear accumulation. Nevertheless, an
increased amount of cyclin B1 phosphorylation was observed in
ICRF-193-treated cells compared with those in G2 4 h earlier. It
is possible that cyclin B1-Cdk1 autophosphorylation does occur
on Ser-126 and/or Ser-128, but that nuclear accumulation re-
quires phosphorylation of all four serines, in particular Ser-
147, which inactivates the nuclear export sequence (25, 26).
Despite the finding that the activity of Plk1 kinase was
significantly inhibited in G2-phase cells experiencing a topoi-
somerase II-dependent checkpoint response, cyclin B1-Cdk1
activity was inhibited only modestly. Therefore, it does not
seem probable that the regulation of Plk1 activity mediates the
activity of cyclin B1-Cdk1 during the G2 arrest induced by
ICRF-193. Our data do not rule out the possibility that Plk1
initially activates the Cdc25C auto-amplification loop because
there was an increase in Plk1 activity during the 4-h treatment
with ICRF-193. Activation of the Cdc25C-cyclin B1-Cdk1 loop
may require only a minimal amount of Plk-1 activity. Inhibi-
tion of Plk1 kinase activity in the presence of substantial cyclin
B1-Cdk1 activity during the ICRF-193-induced G2 arrest may
be explained in part by the previous findings that neither Chk1
nor Chk2 is activated in cells treated with ICRF-193 (4). With-
out Chk1 or Chk2 activation, Cdc25C should be in an unphos-
phorylated state at Ser-216 (9, 10) and, therefore, capable of
interacting with and activating cyclin B1-Cdk1.
Downes et al. (3) first proposed that cells express a topoi-
somerase II-dependent checkpoint that monitors the status of
catenated sister chromatids after DNA replication and pre-
vents exit from G2 until chromatids are sufficiently decat-
enated (3). We recently reported that unlike the DNA damage
G2 checkpoint, the G2 checkpoint response to ICRF-193 was
independent of ATM signaling and occurred in the absence of
Chk1 and Chk2 phosphorylation and in the presence of high
levels of cyclin B1-Cdk1 kinase activity (4). This study provided
further evidence in support of a topoisomerase II-dependent G2
checkpoint that monitors the status of chromatid decatenation
and is distinct from the DNA damage G2 checkpoint. However,
although ICRF-193 does not directly generate DNA damage, it
is not clear if the ICRF-193-induced closed-clamp conformation
of topoisomerase II on DNA mimics a DNA lesion or interferes
with DNA metabolic machinery. It is also possible that ICRF-
193 affects enzymes other than topoisomerase II. Ectopic ex-
pression of the G2-specific human topoisomerase II- in yeast
sensitized cells to killing by ICRF-193 at concentrations that
did not affect endogenous topoisomerase II activity (41). This
result suggests that the observed effects of ICRF-193 are spe-
cifically directed at topoisomerase II and the ICRF-193-induced
closed-clamp conformation of human topoisomerase II on DNA
interferes with DNA metabolism (41). The signal that is gen-
erated by the closed-clamp conformation of topoisomerase II on
human chromatin and which activates ATR signaling to inhibit
Plk1 and delay mitosis is not known. It seems likely that the
signal may be related to the presence of the tethered DNA
strands that are induced by ICRF-193 or the catenated chro-
matids that persist when topoisomerase II function is blocked.
Override of ICRF-193-induced G2 arrest in normal human
fibroblasts using the ATR inhibitor caffeine resulted in clasto-
genesis. Metaphases from cells that bypassed the topoisomer-
ase II-dependent checkpoint displayed chromatid breaks and
exchanges as well as constrictions between daughter chroma-
tids and tangles. ICRF-193 induced similar chromosomal aber-
rations in a muntjac cell line (42). The ICRF-193-induced chro-
mosomal aberrations are likely due to the inhibition of
topoisomerase II catalytic activity producing tethered and cat-
enated chromatids. It is conceivable that these structures in-
terfere with chromatid dis-cohesion producing constrictions
and tangles. Torsional strain placed on the chromatids at such
constriction sites by condensation forces may result in chroma-
tid breakage, and exchange aberrations result from erroneous
repair of juxtaposed breaks. Alternatively the exchange aber-
rations may be the result of a recombination event targeted at
sites of tethering or catenation between non-sister chromatids.
Our results suggest that the checkpoint response that arrests
cells in G2 when topoisomerase II catalytic activity is impaired
may contribute to genetic stability by delaying mitosis until
chromatid catenations have been sufficiently resolved.
The observation that inhibition of topoisomerase II catalytic
activity promotes clastogenesis suggests another mechanism of
genetic destabilization. The high frequency of nonreciprocal
translocations recently observed in prostate cancer cell lines
that were engineered to overexpress HMG1(Y) implicated a
role for HMG1(Y) in DNA rearrangements (43). It was sug-
gested that because HMG1(Y) colocalizes with topoisomerase II
at matrix attachment regions (MARS), the nonreciprocal trans-
locations observed in the cells overexpressing HMG1(Y) may be
a result of topoisomerase II processing of the abnormal DNA
structures caused by HMG1(Y) overexpression. An alternate
explanation for these results is that overexpression of
HMG1(Y) interferes with the ability of topoisomerase II to
decatenate DNA. Inhibition of topoisomerase II decatenatory
activity in cells undergoing chromosome condensation may
cause tension at the catenation sites, resulting in breaks, ille-
gitimate DNA repair, and exchange aberrations.
In conclusion, the studies presented here demonstrate a con-
nection between ATR and Plk1 that regulates entry to mitosis.
It remains to be defined how ATR regulates Plk1 activity.
Because Plk1 does not have any SQ sites, which are preferred
ATR phosphorylation sites (44), it is unlikely that ATR regu-
lates Plk1 directly but rather regulates either an activator or
inhibitor of Plk1. Increased phosphorylation of Plk1 correlates
with an increase in its activity during mitosis (33, 45); there-
fore, one possibility for regulation of Plk1 during G2 checkpoint
responses is the inhibition of a kinase(s) that directly phospho-
rylates Plk1. One candidate is the Ste20-like kinase, Slk1 (ho-
mologous to xPlkk1), which was recently shown to activate
Plk1 during the G2 phase of the cell cycle (14, 46). Future
studies should concentrate on the mechanism by which ATR
regulates Plk1 activity and identify the substrate that acti-
vates ATR during the topoisomerase II-dependent G2 check-
point response.
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